Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00797329
Other study ID # 222CTIL
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 23, 2008
Last updated November 24, 2008
Start date July 2008

Study information

Verified date November 2008
Source BeerYaakov Mental Health Center
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

Aggressive behavior, both in the form of violence toward others (injury-inflicting or homicide) or toward oneself (suicide or self-injures) create problems of patient management, treatment and paroles.

Biological causes of violent crime were hypothesized by Eysenck (1978), who believed that criminality resulted from a nervous system distinct from that of most people.

The prefrontal cortex, regulates planning of motor acts and executive functions, which are critical for inhibitory ability and control of impulsive outburst were found to be impaired in violent subjects (Hoaken et al, 2003; Blair, 2001; Brower and Price, 2001; Filley et al, 2001; Raine et al, 2000; George et al, 2004; Dolan and Park, 2002; Stevens et al, 2003; Raine and Yang, 2006), especially in impulsive offenders murderers (Raine et al, 1997; 1998). Violence act influenced by nonplaning outboards definite as impulsive aggression (Linnoila and Charney, 1999), which one of the most important factor influenced by dangerous behavior in general (for review: Skodol, 1998, Moeller et al, 2001; Pontius, 2000; 2004; Siever, 2008).

Cholesterol and fats have many roles and may influence brain function and behavior through modification of membranes; myelin; enzyme function; absorption and transport of fat-soluble vitamins and toxins; and steroid hormones and through effects on production, reuptake, or metabolism of neurotransmitters (Boston et al, 1996).

Since 80-th a strong association was found between low cholesterol levels and violent behavior, an association that was not due to age, race, sex, or diagnosis (Mufti et al, 1998; New et al, 1999; Alvarez et al, 2000; Golomb et al, 2000; Hillbrand et al, 2000; Troisi and D'Argenio, 2006; Chakrabarat and Sinha, 2006).

Associations between violent behavior, cognitive functioning and total cholesterol level were contradicted with difference in samples and behavioral parameters: homicide, homicide attempts, rape, physical or verbal aggression, complete suicide or suicide attempts, only partially accounted for each measure of behaviors, suggesting that further investigation is warranted. Because of the inconsistencies in the available data, we studied retrospectively a group of criminal offenders with alcohol and drug use. Our analysis of lipid constituents in serum focused on TC, HDL, LDL, and TG.

Significance of the study. It is possible that cholesterol profile is a biomarker and potential predictor of violent in patients with polydrug use.

The purpose of this retrospective study is to investigate the correlations between cholesterol and cognitive profiles in psychiatric patients with violent behaviour. The demographic and criminal records, clinical characteristics, cholesterol profiles, and cognitive performance data of these patients will be will be intercorrelated.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 200
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

1. Age between 19-65 years

2. Men with verified diagnoses of alcohol and polydrug use according to DSM-IV criteria, underwent cholesterol and cognitive assessment, while being incarcerated in maximum-security forensic facility

Exclusion Criteria:

1. Subjects suffering from any clinically significant metabolic disorder (e.g. diabetes, hypo-hyperthiorioidosis, et ctr)

2. Subjects suffering from clinically significant infectional disorder (e.g. tuberculosis, pneumonia, AIDS, active HCV et ctr)

3. Subjects starving or suffering from severe hepatic or kidney dysfunction and insufficiency

4. patients with comorbid diagnoses of schizophrenia, schizoaffective disorder and bipolar mood disorder

5. patients with comorbide mild mental retardation or epilepsy

6. patients with using cholesterol lowering agent

Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Other:
chart review
cholesterol cognitive profiles violent behavior

Locations

Country Name City State
Israel Beer-Yaacov MHC Beer Yaacov
Israel BeerYaakov MHC Beer Yaakov

Sponsors (1)

Lead Sponsor Collaborator
BeerYaakov Mental Health Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary The purpose of this retrospective study is to investigate the correlations between cholesterol and cognitive profiles in psychiatric patients with violent behaviour. 2008-2009 No
See also
  Status Clinical Trial Phase
Completed NCT03165942 - Neuroendocrine Response to Oral Alcohol Administration Phase 1
Recruiting NCT05343039 - Technology Enhanced Adolescent Mental Health (TEAM) N/A
Active, not recruiting NCT04070521 - EEG Monitoring in the Emergency Department
Completed NCT03169244 - Buproprion for Binge Drinking Phase 2
Recruiting NCT05246202 - Personalized Feedback Intervention for Latinx Drinkers With Anxiety N/A
Completed NCT05036499 - PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain N/A
Recruiting NCT04368416 - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Not yet recruiting NCT04557631 - Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02448134 - A Community-Based Strategy for Preventing Underage Drinking N/A
Completed NCT02681406 - Smartphone Based Continuing Care for Alcohol N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Withdrawn NCT01796158 - Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Withdrawn NCT01511679 - Brain-imaging and Adolescent Neuroscience Consortium N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Withdrawn NCT01275391 - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Phase 1/Phase 2
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT01207258 - Brief Intervention for Problem Drinking and Partner Violence Phase 2